Pallas Capital Advisors LLC Cuts Stake in Pfizer Inc. (NYSE:PFE)

Pallas Capital Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 66.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,161 shares of the biopharmaceutical company's stock after selling 100,901 shares during the quarter. Pallas Capital Advisors LLC's holdings in Pfizer were worth $1,271,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer during the 4th quarter valued at $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.37 on Thursday, hitting $24.85. 42,445,910 shares of the company were exchanged, compared to its average volume of 41,112,573. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The stock's 50 day moving average price is $23.01 and its 200 day moving average price is $24.97. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $141.28 billion, a P/E ratio of 17.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.82 earnings per share. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 6.92%. Pfizer's payout ratio is 124.64%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.